United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - pentazocine hydrochloride - oral capsule - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - pentazocine hydrochloride - oral tablet - 25mg

United States - English - NLM (National Library of Medicine)

hospira, inc. - pentazocine lactate (unii: 1p2xib510o) (pentazocine - unii:rp4a60d26l) - pentazocine 30 mg in 1 ml

Canada - English - Health Canada

pfizer canada ulc - pentazocine (pentazocine lactate) - solution - 30mg - pentazocine (pentazocine lactate) 30mg - opiate partial agonists

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - pentazocine hydrochloride (unii: a36bxo4ppx) (pentazocine - unii:rp4a60d26l) - 25 mg

Namibia - English - Namibia Medicines Regulatory Council

fresenius kabi manufacturing (sa) (pty) ltd - pentazocine - injectable solution - pentazocine 30 mg/ ml

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - pentazocine -

Canada - English - Health Canada

sanofi-aventis canada inc - pentazocine (pentazocine hydrochloride) - tablet - 50mg - pentazocine (pentazocine hydrochloride) 50mg - opiate partial agonists

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - piperacillin monohydrate 2 g (as piperacillin sodium 2.085g);  ;  ; tazobactam 250mg; piperacillin monohydrate 2 g (as piperacillin sodium 2.085g); tazobactam 250mg (as tazobactam sodium 0.2683 g) - powder for injection - 2g/250mg - active: piperacillin monohydrate 2 g (as piperacillin sodium 2.085g)     tazobactam 250mg piperacillin monohydrate 2 g (as piperacillin sodium 2.085g) tazobactam 250mg (as tazobactam sodium 0.2683 g) excipient: citric acid monohydrate disodium edetate dihydrate sodium bicarbonate - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of tazocin ef plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: tazocin ef is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, tazocin ef is indicated for the treatment of serious intra-abdominal infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - piperacillin monohydrate 4 g (as piperacillin sodium 4.17g);  ;  ; tazobactam 500mg;  ; piperacillin monohydrate 4 g (as piperacillin sodium 4.17g); tazobactam 500mg (as tazobactam sodium 0.5366 g) - powder for injection - 4g/500mg - active: piperacillin monohydrate 4 g (as piperacillin sodium 4.17g)     tazobactam 500mg   piperacillin monohydrate 4 g (as piperacillin sodium 4.17g) tazobactam 500mg (as tazobactam sodium 0.5366 g) excipient: citric acid monohydrate disodium edetate dihydrate sodium bicarbonate - indicated for the treatment of the following systemic and/or local bacterial infections in which susceptible organisms have been detected or are suspected: 1. lower respiratory tract infections 2. urinary tract infections (complicated and uncomplicated) 3. intra-abdominal infections 4. skin and skin structure infections 5. bacterial septicaemia 6. gynaecological infections 7. bacterial infections in neutropenic patients. full therapeutic doses of tazocin ef plus an aminoglycoside should be used. 8. bone and joint infections 9. polymicrobic infections: tazocin ef is indicated for polymicrobic infections including those where aerobic and anaerobic organisms are suspected (intra-abdominal, skin and skin structure, upper and lower respiratory tract, gynaecological). children under the age of 12 years in hospitalised children aged 2 to 12 years, tazocin ef is indicated for the treatment of serious intra-abdominal infections.